CDKN2A and carcinoma: Carcinoma latency and multiplicity was almost identical for p19 Arf−/− mice regardless of p53 genotype (p53+/+, p53+/−, or p53−/−) (Figure 6A), indicating no cooperation between p19Arf and p53 for malignant conversion per se.